Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?

Sartiani, Laura; Spinelli, Valentina; Laurino, Annunziatina; Blescia, Sabrina; Raimondi, Laura; Cerbai, Elisabetta; Mugelli, Alessandro

doi:10.11138/ccmbm/2015.12.2.135

Cited by 20 publications

(23 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This conflicting result might be related to the low mean age of our population, but might also suggest that disease severity accelerates and offsets the effects of age. No independent association was also observed between sarcopenia and the use of drugs as metformin, ACE‐Is/ARBs and calcium channel blockers, reported to affect muscle mass …”

Section: Discussionmentioning

confidence: 94%

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

Petta

Ciminnisi

Marco

et al. 2016

Aliment Pharmacol Ther

192

152

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 94%

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

Petta

Ciminnisi

Marco

et al. 2016

Aliment Pharmacol Ther

192

152

View full text Add to dashboard Cite

show abstract

“…Given the multidimensional nature of frailty it is likely that interventions that target multiple systems would have the greatest beneficial effects. Other mechanisms that may contribute to protective effects of enalapril on frailty could include effects on muscle, which have been seen in human studies with ACE inhibitors (59,60), or beneficial effects on the heart and vasculature that are not related to blood pressure (61). Future studies should explore these mechanisms further.…”

Section: Discussionmentioning

confidence: 99%

Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice

Keller

Kane

Heinze-Milne

et al. 2018

The Journals of Gerontology: Series A

View full text Add to dashboard Cite

Studies on interventions that can delay or treat frailty in humans are limited. There is evidence of beneficial effects of angiotensin converting enzyme (ACE) inhibitors on aspects related to frailty, such as physical function, even in those without cardiovascular disease. This study aimed to longitudinally investigate the effect of an ACE inhibitor on frailty in aging male and female mice. Frailty was assessed with a clinical frailty index (FI) which quantifies health-related deficits in middle-aged (9–13 months) and older (16–25 months) mice. Chronic treatment with enalapril (30 mg/kg/day in feed) attenuated frailty in middle-aged and older female mice, and older male mice, without a long-term effect on blood pressure. Enalapril treatment resulted in a reduction in the proinflammatory cytokines interleukin (IL)-1α, monocyte chemoattractant protein-1 and macrophage inflammatory protein-1a in older female mice, and an increase in the anti-inflammatory cytokine IL-10 in older male mice compared with control animals. These sex-specific effects on inflammation may contribute to the protective effects of enalapril against frailty. This is the first study to examine the longitudinal effect of an intervention on the FI in mice, and provides preclinical evidence that enalapril may delay the onset of frailty, even when started later in life.

show abstract

“…Interestingly, preclinical and clinical studies suggest that the renin-angiotensin system may participate in the pathophysiology of sarcopenia. [46][47][48] Systemic infusion of angiotensin II is well known to cause skeletal muscle atrophy and wasting in rodents, and this skeletal muscle injury is attributed to the enhancement of oxidative stress 47 and inflammation 48 by angiotensin II. These findings encouraged us to examine the effect of angiotensin II ICV infusion on skeletal muscle of 5XFAD mice.…”

Section: Discussionmentioning

confidence: 99%

Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure

Takane

Hasegawa

Lin

et al. 2017

JAHA

View full text Add to dashboard Cite

BackgroundThe significance of brain angiotensin II in Alzheimer disease (AD) is unclear.Methods and ResultsTo examine the role of brain angiotensin II in AD, intracerebroventricular angiotensin II infusion was performed on 5XFAD mice, a mouse model of AD, and wild‐type mice, and the detrimental effects of brain angiotensin II was compared between the 2 strains of mice. Intracerebroventricular angiotensin II infusion significantly impaired cognitive function in 5XFAD mice but not in wild‐type mice. This vulnerability of 5XFAD mice to brain angiotensin II was associated with enhancement of hippocampal inflammation and oxidative stress and with increased cerebrovascular amyloid β deposition. We also compared the effect of brain angiotensin II on the heart and skeletal muscle between the 2 strains because AD is associated with heart failure and sarcopenia. We found that cardiac compensatory response of 5XFAD mice to brain angiotensin II–induced hypertension was less than that of wild‐type mice. Brain angiotensin II caused skeletal muscle atrophy and injury in 5XFAD mice more than in wild‐type mice.ConclusionsBrain angiotensin II seems to be involved in cognitive impairment and brain injury in AD, which is associated with oxidative stress, inflammation, and cerebral amyloid angiopathy. Further, brain angiotensin II may participate in cardiac disease and sarcopenia observed in AD.

show abstract

Pharmacological perspectives in sarcopenia: a potential role for renin-angiotensin system blockers?

Cited by 20 publications

References 23 publications

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

Sarcopenia is associated with severe liver fibrosis in patients with non-alcoholic fatty liver disease

Chronic Treatment With the ACE Inhibitor Enalapril Attenuates the Development of Frailty and Differentially Modifies Pro- and Anti-inflammatory Cytokines in Aging Male and Female C57BL/6 Mice

Detrimental Effects of Centrally Administered Angiotensin II are Enhanced in a Mouse Model of Alzheimer Disease Independently of Blood Pressure

Contact Info

Product

Resources

About